Genprex

News

Genprex to Present at the 2024 BIO International Convention

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Read More



Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors

Read More

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Ryan Confer Appointed Genprex President and CEO and to its Board of Directors

Read More

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024.

Read More

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments

Read More

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices

Read More

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model

Read More

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read More